Wharton Researchers Examine GLP-1 Drugs’ Possible Effects on Financial Decisions

Tucson, AZ, October 14, 2026 —

Researchers at the Wharton School are investigating whether GLP-1 weight-loss drugs, including Ozempic and Wegovy, may affect financial decision-making by reducing impulses related to shopping and gambling, according to a trending topic originating from kgun9.com in Tucson (Sierra Vista).

The inquiry focuses on a possible connection between the medications and behaviors involving spending or gambling. The available information describes the question being investigated but does not provide findings or say whether the researchers have established any effect.

Details about the research are limited. The summary does not identify the researchers, explain how the investigation is being conducted, or say when it began or is expected to conclude. It also does not specify whether the work involves clinical data, surveys, or another method.

No results, sample size, or conclusions were provided. The information likewise does not quantify any potential change in shopping or gambling impulses, or indicate whether any effects have been observed among people taking the medications.

The reported topic raises a question about whether a treatment associated here with weight loss could also relate to choices in other areas of behavior. At this stage, however, the available account presents that connection as a subject of investigation, not as a demonstrated outcome. It does not establish that the drugs reduce spending or gambling, or that people taking them will experience changes in financial decision-making.

Further details about the study and its findings were not included in the information provided.

Story summarized from the original created by Scripps News Group on www.kgun9.com, see more information here.